GUTS Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $4,999,995.00
Insider Selling (Last 12 Months): $0.00

Fractyl Health Insider Trading History Chart

This chart shows the insider buying and selling history at Fractyl Health by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fractyl Health Share Price & Price History

Current Price: $3.13
Price Change: Price Decrease of -0.15 (-4.57%)
As of 09/6/2024 01:00 AM ET

This chart shows the closing price history over time for GUTS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Fractyl Health Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/6/2024Ajay RoyanDirectorBuy333,333$15.00$4,999,995.001,251,900View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Fractyl Health (NASDAQ:GUTS)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at GUTS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Fractyl Health Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/9/2024Renaissance Technologies LLC14,200$61K0.0%N/A0.030%Search for SEC Filing on Google Icon
8/9/2024Massachusetts Financial Services Co. MA996,383$4.26M0.0%+2.7%2.080%Search for SEC Filing on Google Icon
8/1/2024Rhumbline Advisers7,426$32K0.0%N/A0.016%Search for SEC Filing on Google Icon
5/15/2024M28 Capital Management LP1,856,117$13.74M10.1%N/A3.877%Search for SEC Filing on Google Icon
5/14/2024American International Group Inc.1,339,261$9.91M0.0%N/A2.797%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Fractyl Health logo
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Read More on Fractyl Health

Today's Range

Now: $3.13
Low: $3.06
High: $3.47

50 Day Range

MA: $3.47
Low: $1.78
High: $4.75

52 Week Range

Now: $3.13
Low: $1.74
High: $14.50

Volume

186,489 shs

Average Volume

301,430 shs

Market Capitalization

$149.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Fractyl Health?

Fractyl Health's top insider investors include:
  1. Ajay Royan (Director)
Learn More about top insider investors at Fractyl Health.

Who are the major institutional investors of Fractyl Health?

Fractyl Health's top institutional shareholders include:
  1. Massachusetts Financial Services Co. MA — 2.08%
  2. Renaissance Technologies LLC — 0.03%
  3. Rhumbline Advisers — 0.02%
Learn More about top institutional investors of Fractyl Health stock.

Which major investors are buying Fractyl Health stock?

Within the last quarter, GUTS stock was acquired by institutional investors including:
  1. Massachusetts Financial Services Co. MA
  2. Renaissance Technologies LLC
  3. Rhumbline Advisers